Cyntar Ventures

Cyntar Ventures is a life sciences venture studio dedicated to creating and advancing innovative therapies for inflammatory and fibrotic diseases. The firm operates by identifying high-value biological targets and developing proprietary small molecule candidates through early-stage clinical development. Its primary focus is on metabolic and liver-related conditions, with a lead program centered on next-generation Farnesoid X receptor (FXR) agonists. These candidates are designed to be potent, selective, and non-bile acid-based to improve safety and efficacy profiles compared to existing treatments. By combining deep drug discovery expertise with an agile venture model, Cyntar Ventures aims to deliver transformative treatments for patients with limited therapeutic options. The company is based in the biotechnology hub of Cambridge, Massachusetts, and is led by a team of experienced industry veterans.